NCT05903196 Radiofrequency Ablation Study in LatinX Patients
| NCT ID | NCT05903196 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwell Health |
| Condition | Thyroid Nodule |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-03-12 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-03-12 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Benign thyroid nodules can still create cosmetic, compressive, or hormonal issues for patients. In the past, surgery was typically used to treat thyroid nodules causing the above issues through partial or complete thyroidectomy. More recently, minimally-invasive techniques have been developed to treat these issues. This study is investigating the use of one of these techniques, radiofrequency ablation, in Latinx patients with benign symptomatic thyroid nodules. This procedure is of interest because it avoids the risks of surgery and can be done outside an operating room. The study hypothesis is that the use of RFA is an effective and safe therapeutic option for LatinX patients with a symptomatic benign nodule wishing to avoid surgery.
Eligibility Criteria
Inclusion Criteria: * Subject capable of giving informed consent * Stated willingness to comply with all study procedures and availability for the duration of the study * Subjects over 18 years of age * Subject who self-identifies as LatinX * Subjects who have a benign, symptomatic thyroid nodule * Subjects whose nodule has well-defined margin on ultrasound and is surrounded by at least 2mm of normal thyroid parenchyma in all directions Exclusion Criteria: * Patients who are pregnant, trying to become pregnant, or breastfeeding * Patient who have a cardiac pacemaker,defibrillator , or other electromedical equipment * Patients who have a nodule that is malignant or not predominantly solid (must be \>50% solid by ultrasound) * Patients who cannot give consent * Patients on anticoagulation or dual antiplatelet therapy * Patients with acute illness * People with BP \> 140/90 prior to the scheduled procedure
Contact & Investigator
Daniel Kuriloff, MD
PRINCIPAL INVESTIGATOR
Northwell Health
Frequently Asked Questions
Who can join the NCT05903196 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Thyroid Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05903196 currently recruiting?
Yes, NCT05903196 is actively recruiting participants. Contact the research team at kziskovich@northwell.edu for enrollment information.
Where is the NCT05903196 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05903196 clinical trial?
NCT05903196 is sponsored by Northwell Health. The principal investigator is Daniel Kuriloff, MD at Northwell Health. The trial plans to enroll 44 participants.